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ABSTRACT

The Effects of Thymic Hormones on the Proliferation
of Human Myelogenous Leukemia Ceils
by
Melissa Pompilius
Dr. Biyan L. Spangelo, Examination Committee Chair
Associate Dean of the College of Sciences
Associate Professor of Chemistry
University of Nevada, Las Vegas

Thymosin fraction S (TFS), comprised of an array of small molecular weight
peptides partially purified from the adult bovine thymus gland, contains multiple
biologically active humoral factors. TF5 influences T cell differentiation, lymphokine
production and restores immune deficiencies in a variety of animal models in vitro and in
vivo. Because TF5 generally enhances immune reactivity, we examined the effects of
TFS on the proliferation of HL-60 human promyelocytic leukemia cells. Direct viable
dye cell counting, the MTT reaction, and the clonogenic potential of HL-60 cells were
used to determine cell proliferation. The potency and efficacy of TFS for the inhibition
HL-60 cell proliferation was similar in all three measures of proliferation. In contrast to
HL-60 cells, TFS only induced a modest suppression of human melanoma CRL7686 cell
proliferation. Known qxiptosis inhibitors did not reverse the effect of TFS on HL-60 cell
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proliferation indicating that TFS acts through a non-apoptotic mechanism. The results of
morphological analyses and the TUNEL assay demonstrate that TFS does not induce
apoptosis in HL-60 cells, suggesting that the mechanism of inhibition involves cytostasis.
Further purification of TFS by gel filtration chromatography produces a biologically
active factor of approximately 20 kDa. Since the parent compound is composed of
peptides less than IS kDa, these results suggest the possible formation of oligomers.
Electrophoresis of the active factor on polyacrylamide gels indicates that it contains at
least four components in the S - IS kDa molecular weight range.
These results demonstrate that an activity in TFS exerts an anti-proliferative effect in
human myeloid leukemia cells through a cytostatic mechanism; these studies suggest that
a thymic hormone immune surveillance mechanism may limit the onset of certain types
of leukemia.
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CHAPTER I

INTRODUCTION

Background
Thymus mediated immunity is vital for the preservation of immune function. Age
and disease-related involution of the thymus is accompanied by parallel decreases in the
levels of thymic hormones in the thymic epithelium and the periphery (Schulof et al.,
1981, Berthiaume et al., 1999). As shown in Fig 1, thymic hormone decline is attended
by a decrease in immune reactivity and a corresponding increase in the incidence of age
related diseases (Goldstein et al., 1975). Furthermore, this decline is correlated with an
increase in cancer incidence (Goldstein et al., 1975; Low et al., 1978). While the role of
thymic hormones is poorly defined, growing evidence suggests that, together with
cytokines, they act within the thymus and the periphery to influence T lymphocyte
differentiation and therefore, immune function. Much of the effort to clarify tfie
inununological role of thymic hormones has been performed using a protein extract of
the bovine thymus termed thymosin fraction 5 (TF5). Several component polypeptides of
TF5 have been isolated and purified, but not all of its observed biological effects can be
ascribed to these. TF5 exhibits numerous biological activities that generally enltance
immune reactiviQr (Reviewed in Low et al., 1979; Spangelo et al., 1997). Further,
previously reported results from our laboratory demonstrated that TF5 is an effective
I
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inhibitor of proliferation in rat neuroendocrine tumor cells (Spangelo et al., 1998, 2000).
Other studies have shown that TFS inhibits the growth of some cancer cells in vitro,
including certain murine leukemia cells (Khaw et al., 1973; Schultz et al., 1976; Petro et
al., 1982) and human acute lymphoblastic T cell leukemia cells (Ho et al., 1983, 1983a).
TFS has also been shown to normalize the in vitro mixed lymphocyte response (MLR)
responses of T cells from leukemia patients.
Because TFS generally enhances irrununity and can moderate tumor activity, and
because cancer is generally accompanied by impaired cellular immunity, we tested
whether TFS would inhibit the growth of human HL-60 acute myelogenous leukemia
cells in vitro.
To clarify the relationships between HL-60 cells, cellular immunity, and thymic
hormones in the context of this study, pertinent aspects of several topics are reviewed
briefly: the immune system, the biology and chemistry of thymic hormones, leukemia
and the origin of the HL-60 cell line, and thymic peptides as immunotherapeutic
adjuvants.

Immune System
The white blood cells of the human immune system arise in the bone marrow and
circulate in the blood and lymph. In circulation, they function cooperatively to defend the
body against infection and cancerous body cells. Hemopoietic stem cells in the bone
marrow originate three principal classes of white blood cells: phagocytes, B-cells, and Tcells. Phagocytes leave the bone marrow and become participants in immediate defense
and activation of the immune response. These cells, including macrophages and their
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monocyte precursors, engulf pathogens and enigmatically degrade them.

Antigen

presenting cells, APC's, are macrophages that display protein fragments of engulfed cells
to facilitate immune system recognition of antigens. Some phagocytes become lymphtissue-associated defenders in the liver, spleen, lymph nodes or other tissue. Here, they
trap cellular debris and foreign particles, removing them from circulation (Raven and
Johnson, 1992). Others become mobile defenders circulating in the blood and lymph,
where they phagocytose circulating pathogens that have not yet infected cells. Cytokines
such as interleukin-3 (IL-3), interferon-y ( IFN-y), tumor necrosis factor a (TNFa), and
IL-4 secreted by infected cells and T- cells activate macrophages at local sites of
infection. Upon activation, macrophages in turn secrete cytokines such as IL-1, IL-6 ,
IFN- y and TNFa, which signal the onset of the immune response (Aspinall, 1997). IFNy promotes the development of monocytes into additional macrophages for defense.
Secreted IL-1 activates T-cells that have been stimulated by infected cells and prepares
them to proliferate (Raven and Johnson, 1992). T-cells, upon activation by macrophages,
initiate two parallel immune responses: the humoral immune response and the cellmediated inunune response.
The humoral response is the long-range antibody defense orchestrated by the Bcells. B-cells in the bone marrow develop cell-specific receptors on their surfaces that
allow them to recognize particular foreign antigens. They are then released into the
bloodstream and ^ p h where they differentiate into plasma cells after encountering
pathogens. This is accompanied by protein antigen uptake and presentation on the B-cell
surftue in combination with major histocompatibility complex II (MHC II) molecules.
This complex can then be recognized by antigen specific helper T cell receptors (Raven
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and Johnson, 1992; Aspinall, 1997). Activated helper T cells (T h) and macrophages
(APC’s) also secrete cytokines that induce B-cells to produce large clones of plasma cells
(Raven and Johnson, 1992). The plasma cells secrete specific antibody molecules that
bind antigens and flag the antigen-bearing cells or viruses for destruction.
The cell-mediated immune response involves the destruction of these flagged
cells and abnormal (i.e. cancerous) host cells. To achieve this, Th cells secrete a variety
of cytokines such as IL-2, Macrophage Migration Inhibitory Factor (MMIF), IL-1, IL-4,
and IL-S. IL-2 induces the proliferation of both cytotoxic T cells (Tc) and additional Th
cells. Activated Tc cells express specific receptors that recognize the antigen- MHC
molecule complex on antigen presenting {i.e. dendritic) cells and bind them, inducing
death by lysis. Depending on the cytokine environment, Tc cells can alternatively induce
apoptosis in antigen-bearing cells (Aspinall, 1997). Macrophage Migration Inhibitory
Factor retains macrophages at infection sites (Raven and Johnson, 1992). IL-1, IL-4 and
IL-S participate in B-cell activation (Aspinall, 1997). Th cells also secrete cytokines that
trigger the development and differentiation of T-cells.
This T cell maturation takes place in the thymus, a primary lymphatic tissue
located in the upper thorax just above the heart. The function and physiological role of
the thymus were not known until the 1960’s when studies established that thymectomy or
impaired thymic development in newborn animals {i.e. dogs, guinea pigs, rodents) and
hiunans results in decreased lymphocyte numbers in the tissue and blood, as well as
failure of immunological competence. These studies led to the recognition that primary
transplant, tumor, microbial, and fungal immunities are under thymic control in mammals
(Low and Goldstein, 1978).
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The human thymic core is formed by a fusion of two different types of embryonic
tissue, the 3"* pharyngeal pouch endothelium and the 3"* branchial cleft ectoderm.
Studies in embryonic mice indicate that the ectodermal layers generate the epithelial cells
in the thymic cortex, while the endodermal layers produce the epithelia of the medulla
(Roitt, Brostoff and Male, 1993). In athymic (nude) mouse embryos, this joining of
ectoderm and endoderm is absent, and the thymus never becomes functional (Kendall,
1991). Early in the development process, the thymic foundation formed by these two
layers is divided into two glands by membranes (septa) from the surrounding
mesenchyme. This division allows the entrance of nerves, blood vessels, and other cells
into the cortex and medulla. Monocytes enter and differentiate into macrophages that
populate the cortex and corticomedullary junction, or into interdigitating cells (IDCs) that
reside in the medulla (Kendall, 1991). All of these cells, along with the thymic epithelial
cells, display peptides associated with class 1 and class II MHC molecules, proteins
central to T cell recognition of antigens. The thymus is largest relative to body weight at
birth, and may gradually be reduced in weight with age, as the bulk of the thymopoietic
tissue is replaced with fat cells in the process of “thymic involution” (Kendall, 1991).
The mature thymus provides the microenvironment that controls the development of
immature T-cells, also called thymocytes, into inununocompetent T-cells.
Prothymocytes from the bone marrow enter the thymus devoid of the molecules
characteristic of mature T-cells: the CD3- T-cell receptor complex, and the CD4 or CD8
co-receptors. These double negative (CD4 /CD8 ) cells populate the subcapsular region,
where they proliferate nq)idly and undergo gene rearrangement to express the cell surface
receptor and both the CD4 and the CD8 co-receptors. The resulting double- positive cells
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populate the cortex where they undergo positive and negative selection. Approximately
90% of the double positive cells express receptors that cannot recognize self-MHC
molecules. These fail positive selection and undergo cell death by apoptosis. The
remaining positively selected, self-restricted thymocytes occupy the cortex and
corticomedullary regions, and have increased T-cell receptor expression accompanied by
loss of expression of either CD4 or CDS. Single-positive cells then undergo negative
selection, mainly in the corticomedullary junction, to eliminate strongly self- reactive
thymocytes. Mature T- cells that are self-tolerant and self-restricted leave the thymus via
the corticomedullary venules or lymphatics. The selection process requires extensive
interactions between thymic stromal cells (i.e. macrophages, IDCs, and at least six
subtypes of thymic epithelial cells) and thymocytes involving cytokines (IL’s 1 ,2 ,6 ,7 , 8 ,
IFN- y), and thymic hormones (Bodey, et al., 2000). Two thymic factors that have been
isolated from a partially purified extract of the bovine thymus (thymosin) have been
localized in human thymus glands. Cells lining the cortical surface contain both Ta, and
T^3 , whereas only Ta, can be detected in thymic epithelial cells (TEC) of the medulla.
Further, several peptide components of thymosin can be detected in TECs and
macrophages in the human thymus cortex and corticomedullary junction (Hirokawa,
McClure, and Goldstein, 1982; Schuurman et al., 198S). The location of these peptides in
the thymus, together with experimental data discussed later in this text (Hu, Low and
Goldstein, 1981) indicates that they participate in specific stages of T cell development.
The location of thymosin peptides within the cells of the thymus is illustrated in Fig 2. Tcell maturation peaks during the first year of life, and declines during thymic involution
triggered by aging, acute injury, pregnancy, chemotherapy and other forms of stress
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(Berthiaume, et al., 1999; Kendall, 1991). Concurrent with this decline in thymic function
is a reduction in the secretion of thymic hormones, which have been shown to promote Tcell maturation and to modulate peripheral T-cell responses (Goldstein et al., 1975;
Berthiaume et al., 1999).

Thymosin Fraction S: Purification and
Characterization
The thymic hormones represent a large heterogeneous group of polypeptides that
includes the thymosins, thymulin, thymopoietin and a number of less well-characterized
peptides. The role of these peptides is poorly defined but several lines of evidence
suggest that together with cytokines they exert significant actions within the thymus and
in the periphery that influence T lymphocyte differentiation and hence, inunune function
(Spangelo and Gorospe, 1997). The search for putative thymic hormones began as early
as 1940, when thymic extracts were shown to stimulate the function and development of
lymphoid tissue and to moderate the effects of thymectomy in a variety of animal models
(Low and Goldstein, 1978). Since that time, the biological activities of several thymic
extracts and their derivatives have been tested in both normal and thymectomized animals
and in human clinical trials (Oates, Sztein and Goldstein 1989; Spangelo, 1995). The
results of early attempts to isolate and purify thymic factors that could replace thymusdependent irrununity in normal and thymectomized animals were reported by Goldstein
and colleagues in the mid- 1960s (Klein, Goldstein and White, 1965, 1966).
Thymosin, a stable, biologically active bovine thymus fraction, was identified in
1966, and purified to homogeneity in 1972 (Goldstein, Slater and White, 1966; Goldstein
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et al., 1972).

In 1975, Goldstein and colleagues developed a modified purification

procedure that allowed the preparation of large amounts of thymosin extract, thymosin
fraction five (TF5) (Hooper et al., 1975). The ability to produce significant quantities of
the extract facilitated more extensive studies of its biological and chemical properties.
TF5 contains at least twenty heat stable polypeptides with molecular weights in
the range of 1200-14000. TF5 can be separated on lEF gels into several components. A
nomenclature system based on the resulting isoelectric patterns has divided TF5 into
three bands. Peptides with isoelectric points (pi) of less than 5.0 are known as a-peptides
(acidic). Those with pis of 5.0 to 7.0 are the P-peptides, and those greater than 7.0 are ypeptides. Subscript numbers {i.e. TPa, Tp^) identify the peptides from each band in the
order in which they are isolated (Low et al., 1979). Three peptide components. Ta,, Tp#,
and MB-35 have been purified and sequenced (Low, et al., 1979; Low and Goldstein,
1984). Ta, is a highly acidic (pi 4.2), 3108 MW peptide consisting of 28 amino acids
residues. Tp< has a MW o f4982, a pi of 5.1 and consists of 43 amino acid residues. Both
of these peptides have been proposed to be thymic hormones. Peptide MB-35 is a basic
molecule of 35 amino acid residues with a MW of 3756 (Badamchian et al., 1991).
Thymosin is 99% protein with a small amount of carbohydrate and a minute
amount of nucleotide. Analysis of acid hydrolysates indicates an amino acid composition
high (approximately 50%) in acidic residues, with very few (~ 3%) aromatic residues,
and no tiyptophan. Initial studies demonstrated its biological activity in murine systems
designed to measure lymphocyte function. Thymosin partially restores the responses of
congenitally athymic mouse lymphocytes to mitogens (Con A, PHA), increases survival
times and inunune responses to skin allografts (graft versus host reaction, GvH) in
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neonatally thymectomized mice, induces T cell production in adult thymectomized mice
and enhances the responses of lymphocytes from normal healthy mice to T and B cell
mitogens. Thus, TFS acts in place of the thymus in thymectomized or athymic animals
and boosts immune parameters of healthy animals in vitro. Further, thymosin circulates in
the blood of a variety of mammals. Serum thymosin activity in humans measured by a
radioinununoassay (RIA) shows lower levels with age, and with the presence of
immunodeficiency disease, Hodgkin’s disease, or leukemia (CLL) (Hooper et al., 1975).

TF5: Immune System Stimulation
Subsequent studies have shown that peptide components of TF5 participate in
diverse immune functions. In animal models in vitro and in vivo, TF5 influences
thymocyte development and T cell differentiation, induces lymphokine and cytokine
production, stimulates and restores cellular and humoral immune function, increases
disease resistance and moderates tumor activity. It has similar effects in human models
in vitro. TF5 is not universally successful; its effects appear to be dependent on species,
strain, age, health, and basal immune reactivity of test aiiimals as well as on type of
disease or tumor investigated and TF5 dose and treatment regimen. Clinically, TF5
increases resistance to certain diseases, restores immune parameters during disease states
and moderates the activity of some tumors. Its ability to boost immunity and thwart
disease and cancer activity make it therapeutically attractive for the treatment of certain
diseases. Its efficacy in vitro may be an indicator of whether it will have therapeutic
success for a particular disease.
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Thymosin is extensively involved in thymocyte development and differentiation
in vitro. It induces the differentiation of mouse thymocytes cultured with allogeneic
spleen cells in the presence of antigen (Cohen, Hooper and Goldstein, 1975) and also
induces T cell surface markers (TdT) in murine bone marrow stem cells in vitro
(Pazmino, Ihle and Goldstein, 1978). Receptors for thymosin are present on rat
thymocytes, particularly on cells with medium-sized nuclei rich in condensed chromatin
and on dividing cells (Brelinska and Warchol, 1982). Incubation of rat cortical
thymocytes with TF5 significantly increases the percentage of rosette forming cells
(RFC) in this non-RFC rich population. In contrast, the RF percentage of medullary
thymocytes, which generally do not form rosettes, is not affected by TF5. Spleen fraction
5 has no effect on either population (Kinoshita, et al., 1986). Additionally, thymosin and
its component peptides TP] and TP4 impact various thymocyte maturation sequences in
vivo, such as TdT expression in murine bone marrow cells, and both the early and
terminal stages of differentiation (Pazmino et al., 1978; Hu et al., 1981). It also induces
maturation- stimulated expression of mature T cell markers in normal human thymocytes
(Ho et al., 1983a).
In addition to stimulating differentiation of prothymocytes and thymocytes, pre
incubation with TF5 stimulates mature T cell activity and lymphokine production by
murine cells in vitro (Zatz and Goldstein, 1985). Peripheral blood lymphocytes (PBL)
from thymectomized guinea pigs sensitized with purified protein derivative (PPD) lose
the capacity to produce MMIF. Normal intact PPD sensitized guinea pig PBLs do not
experience this suppression. TF5 restores MMIF production in thymectomized animals
but has no effect on normal intact animals (Thurman et al., 1984). Interleukin 6 (IL-6 ) is
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Il
a pyrogenic cytokine that stimulates pituitary hormone release and participates in T cell
and B cell differentiation and the induction of IL-2 (T cell growth factor) and IL-2
receptor (IL-2R) expression. Thymosin in the presence of mitogen causes a synergistic
increase in lL- 6 production by rat spleen cells in vitro, an activity that is not due to the
Tai or T^ 4 peptide components of TFS (Attia et al., 1993). Previously published data
from our laboratoiy suggests that a novel peptide component of TFS enhances rat glial
cell production of lL- 6 in vitro, and may participate in IL-6 -mediated inflammatory
responses (Tijerina et al., 1997).
Similar effects have been observed in human cell cultures. In the presence of
mitogen, TFS enhances lL-2 production by normal human peripheral blood lymphocytes
(PBL) (Zatz et al., 1984, 1985a; Sztein et al., 1986), an effect that is not due to T al or
Tp4 (Zatz et al., 1984, 1985a). In comparison with other well-characterized thymic
extracts, only one, a closely related porcine preparation exhibited similar activity to TF5
(Zatz et al., 1984,1985a). The preparation also enhances IL-2R expression. This appears
to be a direct effect of TF5, since nullification of IL-2 production does not affect the
outcome (Sztein et al., 1986). TF5 and T al enhance the mitogen-induced high affinity
IL-2R expression by human lymphocytes (PBL) in vitro. This effect is coupled with
increased levels of IL-2 production (Leichtling et al., 1990). Thymosin modulation of the
IL-2/IL-2R system in vitro involves enhanced IL-1 production by macrophages (Sztein et
al., 1989; Hu et al., 1989). In combination with aspirin (acetylsalicylic acid), the
induction of IL-2 synthesis by human PBL is additive, and appears to be mediated by
monocytes (Zatz et al., 1985b). Studies have shown that aspirin and TF5 also induce IFNY production in vitro and in vivo in healthy donors. Together, their effects are additive.
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and both require the presence of macrophages to effect the stimulation (Hsia et al., 1989;
Diezel et al., 1984).
TFS, but not kidney fraction S, stimulates the spontaneous natural killer cell (NK)
activity of human lymphocytes in vitro. The stimulation of NK activity is additive in
combination with recombinant IFN-y (Serrate et al., 1987). In addition to increased IL-2
synthesis, B cell growth factor (BCGF-12kD) production by human PBMC is enhanced
by TFS, reinforcing the evidence that thymus peptides participate in the regulation of
humoral (/.e. B cell) immune responses (Kouttab et al., 1988). Furthermore, TFS
administration in vivo restores the thymus-dependent enhancement of humoral immunity
by estrogen in adult thymectomized rats, indicating that a hormone product of the thymus
contained in TFS enhances a specific humoral immune response (Erbach et al., 1991).

TFS: Restoration of Immune Deficiencies
TFS also stimulates and restores cellular and humoral immune deficiencies
resulting from age, radiation injury, protein deficiency, certain diseases and cancer in
vitro and in vivo.
Mice can be chemically thymectomized by hydrocortisone treatment, resulting in
loss of thymocyte and lymphocyte production. Treatment in vivo with mixed interleukins
{i.e. IL-1, IL-2) prepared from mitogen-stimulated human bufty coat lymphocytes (BCIL; huffy coat interleukins) increases the spleen and thymus weights and cellularity, and
restores fymphocyte subsets and function in chemically thymectomized aged mice. TFS
substantially increases the promotion of T lymphocyte development by mixed BC-IL in
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hydrocortisone treated aged mice in vivo, indicating that the two act together to promote
T lymphocyte development (Hadden et al., 1992).
New Zealand Black (NZB) mice show an age-related loss of T cell functions and
spontaneously develop an autoimmune and lymphoproliferative disease after 16 weeks of
age. Abnormal thymocyte proliferation in these animals is prevented by daily intravenous
injection of TFS (Dauphinee et al., 1974). NZB mice also display an accelerated loss of
antigen-induced depression of spleen DNA synthesis that can be restored in vivo by
injection of young NZB thymocytes. TFS treatment also restores this loss for 1-2 weeks
in vivo. The restoration is repeatable with further TFS treatment (Dauphinee and Talal,
197S).
In an age comparison study of human cells, T cells from normal, healthy older
(6S-103 years) subjects had lowered immune reactivity (MLR) in vitro as compared to
young adults (22-41), although both groups had similar peripheral blood T cell counts.
This decreased reactivity in the aged group was related to an inherent defect in the ability
of the T cells to respond to mitogen. TFS did not enhance the rosette-forming capacity of
T cells (TCR) in either group. However, incubation with TFS increased the MLR
responses of both groups similarly. These results suggest that the decline in lymphocyte
function with age is not due to a decrease in the population of thymosin-responsive cells
(Cowan et al., 1981).
Recovery from radiation injury in mice requires thymus-dependent immunity.
When adult thymectomized, sub-lethally irradiated mice were injected with thymosin,
percent survival and survival time were both increased significantly over spleen extract
and saline treated animals, suggesting that thymosin accelerates thymocyte development
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in absence of the thymus (Hardy et al., 1971). The effect of thymosin on the recovery of
mice from radiation is dependent on the strain and age of mice treated. In three diverse
strains (CS7Bl/KsJ, CS7B1/6, C3H/HeJ, DBA/1) that were radiation injured, all young
(<13 wk) animals showed increased thymocyte responses to lL-1. In the DBA/1 strain,
older animals (>Smo) did not respond to TFS, while age matched C3H/HeJ mice did.
These results indicate that thymic hormones accelerate the inununological recovery of
irradiated murine thymocytes in an age and strain dependent maimer (Neta et al., 1985,
1985a).
Protein deficiency impairs both humoral and cellular immunity. A study of the
immuno-restorative potential of TF5 demonstrated that it exerts differential effects on T
cell functions in variably protein- deficient mice. Well-nourished (normal) mice injected
with phosphate buffered saline (PBS) had significantly increased T cell and B cell
mitogenic responses. PBS treated mice fed low and zero protein diets had smaller
increases in induced mitogenesis. Introduction of TF5 treatment in the normal diet group
gave small increases in mitogenic responsiveness. In the low protein group, TF5
stimulated mitogenic responsiveness to the levels of the control group. In the zero-protein
group, TF5 did not have a significant effect on mitogenic response (Watson and Lim,
1986). In humans, lymphocytes from severely malnourished children had higher RFC
percentages when incubated in the presence of TF5, indicating the presence of immature
thymocytes in circulation in these patients and suggesting a potential therapeutic
application for TF5 in malnutrition (Keusch et al., 1987).
Uraemic animals have increased thymic involution, decreased lymphocyte counts,
and impaired mitogenic responses. When TF5 was administered to severely uraemic rats.
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both thymus weight and lymphocyte populations were restored, suggesting that TF5 can
restore suppressed thymic hormone secretion in vivo. (Ikemoto et al., 1992). Pretreatment
with TF5 also improves the reduced response of thymocytes from severely uraemic rats
to Con A in vitro (Ikemoto et al., 1990). In contrast, TF5 enhances the in vitro mitogenic
response of immature lymphocytes from diabetic rats but decreases the mature T cell
responsiveness (Okimoto et al., 1988).
TF5 restores several depressed immune parameters resulting from disease
conditions and autoimmune disorders in humans, including lymphokine production,
mitogenic responsiveness, and T cell differentiation. For example, IL- 2 levels in HIV
positive pre- AIDS patients were reduced to approximately 20 percent of those in normal
subjects. lL-2 production increased to 35% of normal levels when mitogen- stimulated
peripheral blood lymphocytes from pre- AIDS patients were incubated with TF5. Tal had
no effect (Skotnicki, 1988). In a similar population of patients, TF5 also increased MLR
responses and stimulated mitogen-induced (PHA, PWM) lL-2 synthesis in peripheral
blood mononuclear cells (PBMC) from patients with impaired cell mediated immunity.
These effects are additive when combined with LiCl (Sztein et al., 1987).
In a study of patients with one of several lymphoproliferative disorders, T cells
from patients with systemic lupus erythematosus (SLE) gave increased immune
responses {i.e. mitogenic stimulation, T cell colony formation, and erythrocyte rosette
formation) in the presence of TFS as compared to those from healthy donors. Mitogenic
responses were increased by TF5 in patients with lymphoproliferative disorders (LPD)
(Hazama et al., 1978).

Additionally, incubation with thymosin enhanced immune
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reactivity and induced CD2 receptor expression of peripheral T cells from severely
immunodepressed allogeneic marrow transplant patients (Elfenbein et al., 1980).
TFS restores the suppressor activity of lymphocytes from chronic hepatitis
patients in vitro. Patients with active chronic hepatitis (CAH) had significantly reduced
suppressor cell activity compared to normal subjects. When lymphocytes from both
groups were stimulated with mitogen in the presence of TFS, the cells from the CAH
group had heightened suppressor activity whereas the normal subjects showed no effect
(Mutchnik et al., 1983). Similarly, pre-incubation with TFS normalized suppressor cell
activity in peripheral blood lymphocytes from patients with rheumatoid arthritis (Zatz et
al., 1984a).
TFS also reinstates the loss of immune reactivity due to cancers.

Oral

administration of N-butyl-N- (4-hydroxybutyl) nitrosamine (BBN) induces urinary
bladder cancer in rats. This results in a gradual decline in lymphocyte rosette forming
capacity and a progressive reduction in MLR and mitogenic responsiveness of the rat
thymocytes in vitro that peaks during the hypertrophic stage preceding carcinoma
incidence. Pretreatment of lymphocytes with TFS restored RFC to near control levels
(Kimura, et al., 1986), and improved mitogenic activity (Wada et al., 1987).
Responsiveness was also restored in thymocytes pretreated in vitro with TFS. The
restorative effects were greater in the hyperplastic stage and early in tumor development
(Asakawa et al., 1990).
In a study that tested the in vitro effects of thymosin as an inununothenqieutic
adjunct in humans, cells were taken from patients with disseminated cancers and known,
limited survival times that had received thymosin injections. Patients in this study
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received no other forms of immunotherapy, and thymosin administration was not given
on the same days as chemotherapy. In vitro tests measured the blastogénie and MLR
responses of lymphocytes with and without thymosin. These data were compared to
responses obtained from lymphocytes taken from normal subjects. In both cases,
increased T cell response to thymosin was associated with depressed basal levels of T cell
activity while decreased responses were obtained from subjects with elevated basal
activity. Thus, thymosin tended to normalize lymphocyte responses in vitro without
acting as a mitogen or antigen. Clinically, anecdotal observations suggested patients with
leukemia (ALL, AML, CLL), malignant melanoma and multiple myeloma appeared to
benefit from thymosin therapy, whereas accelerated disease appeared during thymosin
treatment in a male patient with choriocarcinoma. No systematic clinical trial was
conducted, however. Skin test reactivity to antigens was increased in approximately forty
percent of patients, and gradually declined over a 1-2 month period post treatment. This
study indicates that thymosin may have potential as an antitumor agent in leukemia
treatment, that its immunotherapeutic benefit is related to depressed basal lymphocyte
function, and that in vitro responses may be useful in evaluating candidates for thymosin
therapy (Schafer et al., 1976).

TFS: Direct Effects on Disease
And Cancer
In addition to restoring disease and cancer- related immune deficiencies, TFS also
directly affects disease and tumor progression. Shortly after Goldstein and c o lle g e s
reported their initial findings that thymosin enhanced T cell ftmctions in vitro (mitogenic
response, QvH, differentiation), it was tested in the treatment of amyloid disease (e.g.
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Alzheimers) in mice in vivo. This study was logical, since the pathogenesis of amyloid
disease has been related to immune imbalance, particularly with impairment of T cell
functions such as poor response to T cell mitogen, impaired GvH reaction, and lowered
spleen T cell counts. Incidence and severity of amyloidosis induction in low dose (0.5
mg) thymosin -treated animals was reduced considerably, with a moderate improvement
of spleen cell response to T cell mitogen. The increase in mitogenic responsiveness was
higher when TFS was given in high dose (2.5 mg) (Scheinberg, Goldstein and Cathcart,
1976). The effects of TF5 on disease resistance in protein deficient mice compared to
healthy controls are opposite. Lysteria monocytogenes (LM) is associated with impaired
T cell immunity. Protein malnourishment impairs LM resistance in mice. TF5 restored
this resistance, but did not affect NK cell activity. In healthy animals however, TF5
reduced disease resistance and increased NK activity (Petro, Chien and Watson, 1982).
Injections of high doses (0.1 mg/day) of TF5 protected mice from streptozotocin-induced
diabetes and hyperglycemia in vivo. Low dose (0.01 mg/day) TF5 did not have this
protective effect.

Additionally, the effects of thymosin on streptozotocin- induced

diabetic rats also appear to vary depending on the maturational stage of T cells (Tabata et
al., 1989).

In contrast, TF5 is ineffective in the treatment of some disease conditions.

For example, none of three different thymosin dose schedules moderated the incidence or
severity of induced allergic encephalomyelitis in guinea pigs (Woyciechowska, Goldstein
and Driscoll, 1985).
Thymosin facilitates murine host resistance to oncogenic viruses in vivo. Daily
thymosin injections (4.0 mg) increased the percent of mice surviving more than twenty
days after murine sarcoma virus- Maloney (MSV) infection to 69 %, compared to 8
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percent for spleen extract-treated mice and none of control mice (Hardy et al., 1971).
Splenocytes and thymocytes from Lewis tumor bearing mice enhance tumor growth in
syngeneic animals. When TFS-treated thymocytes were used in this system, tumor
growth was significantly decreased (Serrou et al., 1979).
As an anticancer agent, thymosin augmented the rejection of induced Dunning
leukemia in rats. Effectiveness was dependent upon the time after disease induction that
therapy started. The mean survival time for control animals was sixteen days, compared
to greater than 365 days in thymosin treated animals, 60% of which experienced
complete remission. Injection with normal lymphocytes also increased leukemia
resistance. This effect was enhanced three fold when the lymphocytes used to treat
experimental animals were obtained from control animals receiving thymosin injections.
In contrast, rats receiving rabbit anti-thymocyte serum (ATS), an immunosuppressive
agent believed to impair thymocyte function, were more susceptible to the disease. Thus,
the effectiveness of thymosin in augmenting the anti-carcinogenic response may be the
result of enhanced cellular immunity (Khaw et al., 1973).
Thymosin was also a successful adjunct for increasing tumor resistance of mice in
vivo, synergistically increasing the effects of specific macrophage reactivity against
subcutaneous murine MBL-2 or L1210 leukemia injection (Schultz et al., 1976).
Moderate dietary protein deficiency increases in vivo resistance to LI210 murine
leukemia cells as measured by lymphocyte mitogenic response in vitro and serum
corticosterone levels, but not as measured by lymphocyte-mediated cytotoxicity. Protein
deficiency in combination with TF5 administration in vivo enhanced this resistance as
measured by all three parameters. TF5 alone also increased tumor resistance, but was not
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correlated to any of these parameters (Petro et al., 1982). In contrast, administration of
TFS to adult thymectomized mice before and during injection with murine leukemia virus
(MuLV) increased plasma virus titers, viral replication and the appearance of virusinduced membrane antigen, indicating that infection was enhanced (Forger et al., 1976).
Some of the conflicting reports of thymosin’s efficacy as an anti- tumor agent
may be a function of the tumor type under investigation. The injection of BI6 melanoma
cells into adult thymectomized irradiated mice results in lower incidence of metastasis
compared to non-thymectomized control animals. In variants of this tumor, however,
there is an increase in metastasis following thymectomy and irradiation. When the effects
of thymosin were compared in both tumor types, it reversed the effects of thymectomy in
both cases. That is, it increased the metastatic incidence resulting from BI6 melanoma,
and decreased it in the variant model. Thymosin did not affect metastasis in tumor
bearing control animals. Thus, TFS can act in lieu of an intact thymus (Naylor et al.,
1983).
TFS is effective as a primary treatment of some chemically induced murine
tumors in vivo. Pre-incubation of syngeneic bone marrow cells in TFS, followed by
intravenous administration into tumor bearing mice retarded tumor growth and increased
survival time. This effect was not achieved with chemically synthesized compounds
(levamisole, theophylline) that have thymosin-like activity in vitro (Cupissol et al., 1982).
In the case of BBN induced tumor formation however, 60 pg of TFS administered
biweekly did not rescue male NON/shi mice from urinary tract carcinomas or metastasis
of renal pelvic carcinomas (Murai et al., 199S). In contrast, TFS is an effective adjuvant
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combined with S’-deoxy-5-fluorouridine (S’-dFUrd), enhancing its anti-tumor activity in
mouse bladder cancer cells up to four fold (Ikemoto et al., 1999).
Because TFS stimulates the hypothalamic-pituitary-adrenal

(HPA) axis, our

group also examined its effects on rat neuroendocrine MMQ pituitary adenoma and C6
glioma tumor cells in vitro. TFS significantly reduces both the proliferative capacity and
viability of both cell types. Morphological analyses indicate that apoptosis is the anti
proliferative mechanism. The effect on MMQ cells is partially reversed by MMC^ cell
conditioned medium, indicating that these cells secrete an autocrine growth factor that
opposes the actions of thymic hormones. None of the previously purified thymosin
peptides (i.e. Ta,, TP4 , MB-3S and MB-40) have any effect, so the observed inhibition
may be due to a novel peptide component of TFS (Spangelo et al., 1998). These results
suggest that a thymic hormone contained in TFS mediates neuroendocrine tumor
formation and immune functions in vitro and may have therapeutic value in both
capacities (Spangelo et al., 2000).
TFS was tested in vitro as a differentiation agent for human leukemic T cells
(MOLT-3). Incubation with TFS markedly reduces the percentage of cells bearing surface
markers of immature thymocytes (NAI/34) but does not affect expression of post-thymic
T cell markers. Thus, TFS induces signs of differentiation in human leukemic T cells in
vitro (Ho et al., 1983). TFS exerts similar effects in the human thymus-dependent
leukemia (Thy-ALL) cell lines RPMI-8402 and JMl (Ho et al., 1983a).
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TFS; Clinical Studies
Clinically, TFS has been used to replace thymus function in the treatment of
human thymic disorders (i.e. Di George or Nezelof thymic hypoplasia, SCID, primary
immunodeficiency), especially in cases of primary immunodeficiency, where thymus
transplantation is problematic. It has also been employed extensively as an adjunct for
enhancing inununity in “combined modality” studies, particularly in cases where the
primary treatment regimen depletes or impairs the patients’ immune system (as in
chemotherapy). In some cases, however, TFS has been a primary treatment, especially in
autoinunune diseases, or for diseases for which no cure exists or other drugs have been
ineffective (i.e. hepatitis).
in children with primary immunodeficiency, thymosin treatment increased
cellular immune parameters both in vitro and in vivo. Weekly thymosin injections
increased total lymphocytes and percentage of T cells in circulation, and improved
reactivity to skin tests. In vitro, lymphocytes from treated patients formed more T cell
rosettes, some responded better to mitogen stimulation and the MLR assay and some
showed increased immunoglobulin and specific antibody synthesis. Thymosin caused
partial reconstitution of cellular inununity in patients with thymic hypoplasia who have
an existing population of thymocyte precursors, and induced an in vitro increase of T cell
rosette formation by lymphocytes from patients with DiGeorge syndrome. Iti contrast, it
had no effect in vitro or in vivo on the parameters for patients with SCID, severe
combined immunodeficiency disease (Wara and Amman, 1976).
The immunorestorative potential of thymosin was tested clinically in an attempt
to shorten the extended periods needed for marrow graft patients to recover
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immunologically. Despite its success in restoring cellular immunity to lymphocytes from
marrow transplant patients in vitro, TF5 did not significantly alter immune or disease
stabilization parameters for human marrow graft recipients (Witherspoon et al., 1983).
TFS is an effective immunorestorative adjunct in the treatment of some patients
with advanced refractory cancer. In one clinical trial, a single treatment of thymosin
resulted in significant improvement in several immunoassays designed to measure
humoral and cell-mediated immune responses (i.e.. E-rosette, MLR). Although no
decrease in tumor volumes was observed, two patients (14%), one with lung cancer and
one with thymoma, had disease stabilization for up to six months. No significant
toxicities, side effects, or complications resulted from thymosin therapy. Improvement in
immune assays decreased by 48-72 hours, indicating that repeated thymosin
administration is necessaiy to maintain benefits (Dillman et al., 1983). In contrast,
sustained TFS administration (120mg/mL biweekly) to patients with advanced colorectal
cancer that had failed to respond to standard therapies, or patients with hypernephroma
who had previously failed Tai therapy, elicited no response in similar assays.
Additionally, no antitumor effects were observed in this trial (Dillman et al., 1987).
Similarly, administration of TFS (60 mg/m* s.c. twice weekly) to small cell lung cancer
patients undergoing induction chemotherapy and radiation therapy,

including

prophylactic cranial irradiation, did not alter response rate, response duration, survival
rates, immune function, or lymphocyte counts (Scher et al., 1988).
Male homosexuals serum-positive for HTLV-lII who entered thertqry with
abnormal T cell balances and received 60mg of subcutaneous TFS daily for ten weeks
exhibited improvements in T- lymphocyte immune (MLR) reactivity and transient
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normalization of mitogen-induced IL-2 production. TFS did not alter serum antibody
titers, and other dose regimens (30, 120 mg) were ineffective. The responses could not be
sustained when TFS was administered only twice weekly. At a median 20-month follow
up, none of the patients (6/14) whose MLR improved in response to TFS had progressed
to AIDS. These results indicate that TFS has therapeutic value for the treatment of
immune deficiencies in serum-positive HTLV-111 patients in appropriate doses and in
combination with antiviral drugs (Schulof, et al., 1986).
Several autoimmune disorders possibly related to abnormal T suppressor
functions responded well to TFS treatment in initial clinical studies. Four patients with
systemic lupus erythematosus, and one with rheumatoid arthritis and Sjogren’s syndrome
were given thymosin injections for 2 to 3S months. All patients had higher levels of T
lymphocytes in circulation after treatment. Pretreatment assays were positive for
cytotoxicity for all patients, and declined to zero during the course of therapy. Of four
patients exhibiting clinical improvement, one had disease stabilization (Lavastida et al.,
1981).
Preliminary clinical results indicate that thymosin is effective as a primary
treatment for chronic hepatitis B. Thymosin treated patients were compared to patients
receiving placebo, and both groups were compared to healthy volunteers. Six of seven
thymosin-treated patients responded to therapy. One of the five placebo-treated patients
experienced complete remission of disease, while the other four showed no response. In
thymosin patients, serum HBV DNA disappeared and serum ALT levels were
significantly lower than placebo patients. The thymosin group was negative for serum
HBV DNA and had normal ALT levels at two years post treatment Thymosin also

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

25
reversed the decrease in peripheral blood lymphocyte, CD4 and CD3 counts caused by
the disease, and these patients had elevated levels of IFN-y synthesis by peripheral blood
mononuclear cells (PBMC) as compared to the placebo group and to healthy volunteers.
Thymosin therapy was also associated with decreased liver inflammation and tissue
damage, and cessation of viral protein production (HbsAg) and HBV DNA replication.
Since the thymosins are not known to have antiviral properties in vivo, these clinical
results may be due to thymic peptide modulation of cellular and humoral immune
responses (Mutchnik et al., 1991).
Patients undergoing intensive chemotherapy to induce remission of small-cell
lung cancer did not exhibit higher complete response rates upon the addition of thymosin
therapy (60 mg/m^ biweekly for six weeks). However, among the complete responders,
those who received thymosin had prolonged disease remission and subsequently,
signiflcantly prolonged survival times (Cohen et al., 1979).
In a clinical trial evaluating the efficacy of TF5 as a primary therapy in advanced
renal cancer, thymosin treatment of patients who had previous nephrectomy resulted in
partial regression in 15%, and disease stabilization in 10% of patients. All patients who
responded to therapy presented with lung métastasés prior to treatment. One patient had a
50% reduction in diameter of a lung lesion, accompanied by complete clearing of a small
pleural effusion, after four weeks of high dose (120mg/m2) thymosin administration. In
this trial TF5 was as effective as chemotherapy in the treatment of advanced renal cancer,
without the detrimental side effects. These results also suggest that thymosin may be
effective in the therapy of lung cancer patients (Schulof et al., 1984).
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Thus, TFS and its component peptides participate extensively in immune
functions, and can improve host defense by stimulating both cellular and humoral
immunity. Additionally, they can directly inhibit disease and tumor progression. Their
effects vary depending on the experimental model system and on the type of disease or
cancer involved. Their effectiveness for a particular function in vitro may be an indicator
of therapeutic usefulness.

Principle Hypothesis of This Study
Because TFS is a potent immune enhancing agent that also exerts anti-cancer
effects, and because the leukemias are cancers that induce severe immune deficiency, we
hypothesized that TFS would act directly on human leukemia cells to inhibit their
proliferation. We conducted experiments to test the specific hypotheses that (1) thymic
peptides inhibit the proliferation of human HL-60 myeloid leukemia cells, (2) this
inhibition is due to a putative peptide component of TFS, and (3) the mechanism of
inhibition is apoptosis.

Leukemia and the Origins of the HL-60 Cell line
The leukemias are cancers that result from the unregulated growth and abnormal
differentiation of hematopoietic cells and their precursors (stem cells) in the bone
marrow. The leukemic cells proliferate more and survive longer than normal cells,
gradually building up in the bone marrow and inhibiting the production of functional
blood cells. Eventually, aberrant nonfunctional leukocytes spill into the bloodstream and
ultimately invade other organs and tissues, thwarting normal function.

Impaired
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hematopoiesis

leads to deficiencies of red blood

cells (anemia), platelets

(thrombocytopenia) and phagocytes (neutropenia, monocytopenia), and disrupts the
ability to mount a competent immune response.
There are four major classifications of leukemia; lymphocytic leukemias involve
abnormal development of lymphocytes, while myelogenous (granulocytic) leukemias
affect cells of the myelocytic lineage. Both of these may be acute or chronic. Acute
leukemias progress very rapidly; chronic disease progresses more slowly then converts to
rapid progression or “blast crisis” in the terminal stage.
Acute myelogenous leukemia (AML), also known as acute non-lymphocytic
leukemia (ANLL) or acute granulocytic leukemia (AGL), results from neoplastic
transformation of a hematopoietic stem cell in the bone marrow. The cause of
transformation is generally not known, but several risk factors have been identified.
These include advancing age (-50% of new cases occur after age 65), impaired immune
function, exposure to industrial chemicals (i.e. benzene), or exposure to irradiation.
Paradoxically, chemotherapy, the primary treatment for AML, is also a major risk factor
for the disease. In fact, AML commonly occurs as a secondary malignancy in patients
previously treated for cancer (Belcher, 1993; McAllister, Horowitz and Gilden, 1993).
Chemotherapy also contributes to another risk factor for leukemia, impaired
immune function. It is unclear whether immunodeficiency allows leukemia to develop or
whether the neoplasm and the immune defect arise from the same genetic injury. Several
congenital immunodeficiencies however, are associated with increased AML incidence
(i.e. SCID, neutropenia, Fanconi’s anemia), and the course of AML itself results in severe
immime defects (i.e. neutropenia, anemia, thrombocytopenia). Without competent

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

28

immune defense, patients are increasingly susceptible to infections (Wiemik et al., 1991;
Belcher, 1993; McAllister, Horowitz and Gilden, 1993). Impaired immunity is also
associated with poor prognosis, especially if T cell dependent immunity is affected, as
exemplified in the case of Hodgkin’s disease. Hodgkin’s disease is a neoplasm affecting
the lymph nodes, spleen and liver. Otherwise normal patients with Hodgkin’s disease
have a 66% higher 5-year survival rate then patients with deficiencies involving cellmediated immunity (Wiemik et al., 1991). Because of these factors, there is an emphasis
on restoring and maintaining inunime functions during AML therapy.
The HL-60 human acute myelogenous leukemia cell line was established from the
peripheral blood of a patient with AML (Collins, Gallo and Gallagher, 1977). It was
originally classified as derived from acute promyelocytic leukemia APL FAB- M3, a subtype of the myelogenous leukemias, although the cells were noted to lack several features
characteristic in APL cells (Collins et al., 1977; Gallagher et al., 1979). It was later
reported that HL-60 morphology is more accurately classified as AML FAB- M2, an
acute myeloblastic leukemia with some markers of maturation (Dalton et al., 1988).
This cell line is susceptible to HIV-1 and HTLV-1 viruses. The cells form
colonies in agar and produce myeloid tumors in nude mice. HL-60 cells are commonly
used for pharmacodynamics, induction of differentiation studies and antitumor testing
(Gallagher et al., 1979; Koefiler and Golde, 1980).
Since TF5 generally restores immune deficiencies and inhibits the activity of
some tumor cells, we tested its effects on human myelogenous leukemia cells.
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CHAPTER 2

MATERIALS AND METHODS
Chemicals and Reagents
MTT (3-(4,S-dimethylthiazol-2-yl)-2,5-diphenyl tétrazolium bromide, z-Val-AlaAsp-CHzF (zVAD-fmk), etoposide (VP-16), sphingomyelinase, horse heart cytochrome
c, trypsin, bradykinin, aprotinin, sephadex G-SO gel filtration beads, reagent grade
isopropanol, methanol, glacial acetic acid, hydrochloric acid, dibasic sodium phosphate,
ammonium sulphate, P-mercaptoethanol, Folins reagent and agar were purchased from
Sigma Chemical Company (St. Louis, MO). Dr. Ronald Gary, University of Nevada Las
Vegas (Las Vegas, NV) kindly provided DNP-Asp Blue Dextran and Coomassie blue
stain solution. Penicillin G-streptomycin sulfate antibiotic mixture, streptomycin sulfate,
RPMl 1640, L- Glutamine, MEM sodium pyruvate solution, MEM non-essential amino
acids solution, and trypan blue stain were purchased from Gibco BRL (Grand Island,
NY). Heat-inactivated Fetal Clone I serum was purchased from HyClone, USA (Logan,
UT). Dr. Mahnaz Badamchian, George Washington University (Washington, DC)
generously provided thymosin fraction 5 (TFS) and thymus acetone powder (TAP). Dr.
W. David Jarvis, University of Texas at Houston (Houston, TX) kindly provided the HL60 cell line. The CRL7686 cell line was obtained from the American Type Tissue Culture
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Collection (Rockville, MD). Novex™ Tris-glycine 4-20% SDS (sodium dodecyl sulfate)
and NuPAGE™ Bis-tris 12% pre-cast electrophoresis gels, Novex^ precast vertical lEF
gels. Mark 12™ electrophoresis protein standard mixture, tris-glycine SDS running
buffer, tris-glycine SDS sample buffer, NuPage MES (2-(N-morpholino) ethane sulfonic
acid) SDS running buffer, lEF anode buffer, lEF cathode buffer pH 3-10 and pH 3-7, lEF
sample buffers pH 3-10 and pH 3-7, and colloidal blue staining kit were purchased from
Invitrogen Corporation (Carlsbad, CA).

HL-60 Cell Culture
The HL-60 cell line was maintained in continuous culture in a humidified
atmosphere of S% C02-95% air at 37"C in phenol-free RPMI-1640 supplemented with
10% heat-inactivated fetal bovine serum, sodium pyruvate, nonessential amino acids and
antibiotics. Cells were sub-cultured every 3-4 days. Cells were removed from tissue
culture flasks, rinsed three times with serum- free RPMI (sfRPMI), counted by
hemacytometer, and either placed in continuous culture (1.0 xl0‘ cells per 25 cm* flask)
or used in cell culture assays.

Viable Dye Exclusion Assay
Initial experiments consisted of three groups of cells: one was pre-incubated in the
presence of TFS for 24 h and then rinsed and assayed, a second was exposed only to
vehicle (RPMI 1640, supplemented), and a third was assayed in the continuous presence
of TFS. All groups were cultured at an initial plating density of 1.0 xl0‘ cells/flask in 25
cm^ tissue culture flasks and aliquots were removed and counted by hemacytometer each
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day for four days using the viable dye (trypan blue) exclusion assay. Cells were also
cultured in 12-well culture plates (240 x 10^ cells/3ml/well; Costar, Fisher Scientific,
Santa Clara, CA) and treated with vehicle or TFS for 24-96 h for the determination of cell
viability and proliferation using the viable dye exclusion assay. For the TFS metabolism
assay, cells were cultured in 2S cm^ tissue culture flasks (1.0 x 10^ cells/flask; Greiner
Labortechnik, ISC Bioexpress, Kaysville, UT) in the presence of either TFS, HL-60
conditioned medium, HL-60-conditioned TFS or vehicle, and aliquots were removed and
counted by hemacytometer each day for four days
For the MTT assays, HL-60 cells were incubated in 96-well plates for 72 h (20 x
10^ cells/0.2 ml/well; Greiner) in the presence of either TFS, fractions of TFS, other
thymus preparations, or vehicle for the determination of cell viability and proliferation.
In addition, differing numbers of cells (S-30 xlO^ cells/well) cultured in 96-well tissue
culture plates were exposed to TFS for 96 h. After incubation, 20pl of Smg/mL MTT was
added to each well. After a 4 h incubation period, ISOpl was removed from each well,
and replaced with an equal volume of 0.04 M HCl/isopropanol. After overnight
incubation in darkness, the dissolved MTT crystals were quantitated. Optical densities
were obtained using a test wavelength of S70 nm and a reference wavelength of 630 nm
(Dynatech MRS000 microelisa spectrophotometer, Chantilly, VA).

Clonogenic Assay
Cell proliferation was also evaluated using a cloning assay. HL-60 cells were
removed from continuous culture, rinsed three times with sfRPMI and counted ly
hemacytometer. Various cell numbers (SO-1000 cells/well) were dispersed into 12-well
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plates in a single-layer soft agar system containing RPMI, 20% heat- inactivated fetal
bovine serum, and 0.3% agar. The plates were incubated at 37°C in 5% C02-9S% air.
The resulting colonies (>S0 cells) were counted 14 days after plating. In TFS
pretreatment experiments, cells were removed from continuous culture, rinsed with
sfRPMI and 1.0 x 10^ cells/lOmL were incubated in culture flasks either in vehicle, or in
100 - 800 pg/mL TFS for 24 h. They were then rinsed, counted and plated in the agar
system for enumeration of colony formation after 14 days of incubation. Using the same
protocol, cells were also incubated for 24h with vehicle, 400 and 800 pg/mL TFS, or 40
and 80 pg/mL of biologically active RP-HPLC fractions of TFS and plated in the agar
system. In time-course experiments, 1.0 x 10^ cells/lOmL were incubated in culture
flasks either in vehicle, or in 400 and 800 pg/mL TFS for 3-24 h. The end points of
incubation were coordinated so that all cells were removed firom culture or treatment,
rinsed and plated in the agar system at the same time. To study the effects of apoptosis
inhibitors, cells were removed from culture as before, and one group was pretreated for
30 min with the apoptosis inhibitor ZVAD-fmk (dissolved in DMSO), and then incubated
in the presence of 800mg/mL of TFS. Other groups were incubated with vehicle, DMSO
(as a control for the ZVAD-fink carrier) or 800 pg/mL TFS. All groups were plated in the
agar system at the same time. In similar experiments, cells were pre-incubated with
ZVAD-fink for 30 min and then incubated with sphingomyelinase (Smase), or etoposide
or 800pg/mL TFS, or cells were incubated with 800pg/mL TFS, DMSO, or vehicle for 24
h, and then plated in the agar system. As before, incubation times were coordinated so
that cells were rinsed and plated at the same time.
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Partial Purification of TF5
TFS was prepared from freshly frozen calf thymus as described by Hooper et al
(197S). Preparative reverse-phase high performance liquid chromatography (rpHPLC) of
TFS was performed as described as described by Badamchian, et al (1990, 1991). TFS
(I S g) was applied to a 5-prep HPLC system equipped with a model 481 variable
wavelength detector with a semi-preparative flow cell (280 nm) and a 300 x SO mm d-pak
300 A ISpm C|8 column (Waters Chromatography Division of Millipore Corp., Milford,
MA). Eluent A was 0.02 M ammonium acetate (pH 6.8) and eluent B was acetonitrile. A
60-min linear gradient from 0-80 % B was run at a flow rate of 80mL/min. TFS was
dissolved in the initial solvent A, applied to the column through a port in the solvent
delivery system, and one- minute fractions were collected for sixty minutes. Actual
protein concentrations were determined using the Lowry assay (Lowry et al., 19S1).
Aliquots from each of the 60 fractions (S-lSpl/well) were added to cultured tumor cells.
The cells were incubated for 4 days, and the extent of proliferation was determined using
the MTT assay.

Size-Exclusion HPLC Analysis of TFS
TFS was further separated by size-exclusion HPLC. 20 or SOpL of TFS dissolved
in lOmM dibasic sodium phosphate buffer was injected onto an in-line colurrm system
composed of a Macrosphere GPC lOOA 7p column 2S0 mm x 4.6 nun (i d.) followed by
a Macrosphere GPC 60A 7p colurrm of the same dimensions (Alltech Associates,
Deerfield, IL), with a 10 mM dibasic sodium phosphate running buffer. Detection was
obtained at 220nm (Spectroflow 7S7 absorbance detector, Kratos, Ramsey, NJ). The
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resulting protein peaks were analyzed by PeakSimple Peakll Chromatography Data
System software (SRI Instruments, Torrance CA.). The fractions collected were
lyophilized under vacuum in centrifugal desiccation unit (Savant Instruments, Inc.,
Holbrook, NY), and re-suspended in sterile ultrapure water for further analysis.

Gel filtration Chromatography
Purification of TFS components was achieved by gel filtration chromatography. A
Kontes (Fisher Scientific, Santa Clara, CA) 1.5 x 30 cm (50 mL) filtration column was
packed with Sephadex G-50 beads in lOmM sodium phosphate buffer adjusted to pH 7.0.
The flow rate was maintained at 1.40 mL/min. The outer and inner column volumes were
defined as the elution volumes of blue dextran (5 mg/mL) and DNP-Asp (0.5 mg/mL)
respectively. Bradykinin MW -1050), cytochrome c (MW -12,000), and trypsin (MW
-24,000) were used as protein standards. From their elution volumes, the elution
coefficient, K was determined, using the following equation:
K = (Ve-Vo)/(V,-Vo)
Where V, is the elution volume of a solute, Vo is the volume outside of the beads in the
column, and V, is the total volume occupied by the gel bed.
A plot of the log of the molecular weight versus the K for the standard proteins
was used to estimate the molecular weight of the TF5 Auctions. TF5 dissolved in lOmM
sodium phosphate was applied to the column and the resulting fractions were collected
and stored at -70°C. They were later lyophilized under vacuum in centrifugal desiccation
unit (Speedvac SC 100, Savant Instruments, Inc., Holbrook, NY), and re-suspended in
sterile ultrapure water for further analysis.
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Electrophoresis
SDS PAGE electrophoresis (Laemmli) and isoelectric focusing were carried out
in a mini-vertical electrophoresis system (Novex Xcell Surelock Mini-Cell, Invitrogen)
on pre-cast 10- well gels in accordance with the manufacturers protocols (InvitrogenNovex™). Initial SDS PAGE gels were 4-20% tris-glycine polyacrylamide gels buffered
to pH 8.7 with a tris-glycine-SDS (2.9%, 14.4%, 1%) running buffer (upper and lower
chambers) pH adjusted to 8.3. The sample buffer was composed of 0.5 M Tris-HCl, 20%
glycerol, 10% (w/v) SDS, 0.1% bromophenol blue, pH adjusted to 6.8. The samples
were reduced by adding 2.5% P-mercaptoethanol and heating at 85° C for two minutes
immediately prior to loading. 5-50 pg of sample was loaded into each well, and
electrophoresis was carried out at 25 mA starting and 8 mA ending current (125V
constant) for approximately 60 minutes. The gels were subsequently stained in a solution
containing 0.06% Coomassie Blue, 50% methanol, and 7% glacial acetic acid in ultrapure
water for approximately 12 hours, and then de-stained for approximately 16 hours in a
destain solution containing 10% methanol and 7% glacial acetic acid in ultrapure water.
Gels were then permanently fixed on a slab gel drier (SGD 4050 Slab Gel Dryer, Savant
Instruments, Inc., Holbrook, NY).
Electrophoresis was also carried out on 10-well 12% Bis-Tris-HCl (Bis[2hydroxyethyl]imino-tris[hydroxymethyl]methane-HCl) buffered (pH 6.4) polyacrylamide
gels (NuP%e ™Bis-Tris gels) in accordance with the manufacturer’s protocol
(Invitrogen-Nupage). The lower chamber ruiming buffer was composed of 1.00 M MES,
1.00 M Tris base, 69.3 mM SDS, and 20.5 mM EDTA (ethylenediaminetetraacetic acid).
The composition of the upper (iimer) buffer chamber running buffer was the same as for
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the lower, with the addition of 0.25% of Nupage™ antioxidant (Invitrogen) containing
dimethylformamide and sodium bisulfite. The sample buffer (pH 8.5) was composed of
40% glycerol, 6.82% tris base, 6.66% tris HCl, 8% LDS (lithium dodecyl sulfate), 0.06%
EDTA, 0.075% Serva Blue 0250 stain, and 0.025% phenol red. Two gels were run
simultaneously. 3>5pg of sample was loaded onto each well, and electrophoresis was
carried out at 200 V constant voltage for approximately 30 minutes. Gels were then
shaken in fixative consisting of 50% methanol, 10% glacial acetic acid and 40% ultrapure
water for 10 minutes, stained in colloidal blue stain solution and destained in ultrapure
water according to the protocol provided by the manufacturer (NuPage ™ Colloidal Blue
Stain Kit-lnvitrogen). Gels were stored in 20% ammonium sulfate solution at 4 °C until
drying.

Cytological Analysis
Cytological characterization of apoptosis was performed by Jarvis and colleagues
as previously described (1997). To examine cells for the apoptotic morphological
changes, they were stained with 20% Wright-Giemsa stain and assessed for the
expression of nuclear and cytoplasmic condensation, membrane blebs, apoptotic nuclear
bodies and cell shrinkage by light microscopy (LM). At least four 50-cell fields were
scored.
To detect apoptotic DNA damage, cells that were prepared and fixed as described
(Jarvis et al., 1997) were stained to detect broken DNA by treatment with TdT in the
presence of fluorescein isothiocyanate-dUTP (FITC-dUTP) and then counterstained for
intact DNA with propidium iodide. At least four 50- cell fields were scored by
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fluorescence microscopy (FM) by evaluation of increased direct fluorescence of endlabeled double-stranded DNA.

Statistical Analysis
Analysis of variance (ANOVA) and the Bonferroni analysis for multiple
comparisons were used for statistical evaluation of the data. A P-value of < 0.05 was
considered significant. Unless noted otherwise, data are expressed as the mean ± SEM of
groups consisting of 4 observations.

Unless otherwise noted, each experiment was

performed independently at least 3 times and representative results are reported.
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CHAPTER 3

RESULTS
Previously reported results using MMQ (rat pituitary adenoma) and C6 (rat
glioma) cells determined that TES is an effective inhibitor of proliferation in
neuroendocrine tumor cells (Spangelo et al., 1998, 2000). Because TES exhibited these
anti-proliferative abilities on MMQ and C6 cells, and because it is a known stimulator of
T cell-mediated immunity, we examined its capabilities as an inhibitor of human
leukemia cell proliferation.

Continuous Culture of
HL-60 cells
In continuous culture, HL-60 cells proliferated rapidly, doubling in concentration
(cells/mL) every 24-30 hours (Eig 4). Cell viabilities consistently remained above 95%
during the culture period (data not shown). Cells were removed from culture and assayed
during the logarithmic phase of proliferation that occurred at 24-96 hours.

Effects of TE5 on HL-60 Cell Proliferation:
Dye Exclusion and MTT Assays
TES (100-800 pg/mL) suppressed the proliferation of HL-60 cells during 24-72
hours of exposure (Eig 5), with cell viability being reduced to 60% within 48 hours as
38
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determined by the viable dye exclusion assay (Table 1). At 400 pg/mL TFS, cell
proliferation was inhibited by 50% (EDso) and 800 pg/mL TF5 consistently achieved
maximal inhibition. This anti-proliferative effect increased with time, demonstrating
maximal inhibition at 72 hours of incubation (Fig 6).
In the MTT assay, TF5 was less effective as an anti-proliferative agent at higher
cell densities (Fig 7). While all concentrations of TF5 inhibited proliferation at initial
plating densities of 5 and 10 x 10^ cells per well, higher concentrations of TF5 were
required to significantly inhibit cell proliferation at greater cell densities. An initial
plating density of 20x10^ cells/well allowed was chosen for all subsequent MTT reaction
assays. This initial density allows a clear TF5 dose-response with an EDso at
approximately 400 pg/mL and maximal Inhibition at 800 pg/mL, consistent with the
viable dye exclusion assay.
To examine the mechanism by which inhibition was effected, we tested the ability
of HL-60 cells to rebound from 24 hours of pretreatment with 800 pg/mL of TF5 as
measured by the viable dye exclusion assay. Cells that had been pretreated with TF5 and
then rinsed were re-cultured in vehicle and compared to cells cultured only in vehicle,
and cells cultured in vehicle with 800 pg/mL of TF5. Pretreatment with TF5 (24 hours)
produced the same capacity for suppressed proliferation as continual treatment (Fig 8).
These results suggested that TF5 induced its anti proliferative effects within 24 hours. Its
removal did not diminish the observed inhibition. Because of this, we hypothesized that
the cells metabolize a consumable factor found in TF5. To test this hypothesis, the
supernatant from cells treated with 800 pg/mL TF5 for 24 hours was applied as a
conditioned medium to a naive cell culture (HL-60-conditioned TF5). This was compared
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to cells cultured in vehicle, 800 pg/mL TFS, and 800 pg/mL TFS dissolved in HL-60
conditioned medium. The proliferation of cells treated with TFS-conditioned medium
was similar to that of cells cultured in vehicle. In contrast, the effects of treatment with
800 pg/mL TFS were the same in both vehicle and HL-60-conditioned medium (Fig 9).
These preliminary results support our hypothesis.

Effects of TFS on HL-60 Cell Proliferation:
Clonogenic Assay
Cell proliferation can also be measured using a single layer soft agar system to
determine the capacity of the cells to form colonies. In contrast to the viable dye
exclusion and MTT assays, clonogenic potential is a direct measure of cell viability and
proliferative capacity. Therefore, the clonogenic potential of HL-60 cells was tested in
the presence and absence of TFS. Initial experiments demonstrated that the clonogenic
potential of HL-60 cells was dependent on initial cell number (Fig 10). We chose 300
cells/well as the initial cell plating density in all subsequent experiments because this cell
concentration allowed concentration-dependent effects of TFS similar to those observed
in the viable dye exclusion and MTT assays.
The ability of TFS to inhibit the clonogenic potential of HL-60 cells was tested.
Cells were pretreated with concentrations of TFS ranging from 100-800 pg/mL. TFS
reduced the ability of HL-60 cells to form colonies in a dose dependent manner. The
dose producing S0% inhibition (EDso) was 400 pg/mL and 800 pg/mL was maximally
effective, as with the MTT assay (Fig 11). To determine the minimum incubation period
required for inhibition of colony-forming potential, pretreatment time course experiments
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were conducted. Exposure to 400 pg/mL for as little as 4 hours produced inhibition of
colony formation. Exposure to 800 pg/mL of TFS for 4 hours significantly inhibited
colony formation, and 8 hours essentially completely inhibited HL-60 clonogenic
potential (Fig 12).

Effect of zVAD-fmk on TFS Inhibition
of HL-60 Cell Proliferation
The mechanism of inhibition was investigated using the known apoptosis
inhibitor,

z-Val-Ala-Asp-CHjF

(zVAD-fmk),

a

cell-permeable,

broad-spectrum

irreversible caspase inhibitor. We compared the ability of zVAD-fmk to reverse the
effects of TFS to its ability to reverse the effects of etoposide, a known apoptosis inducer.
In these experiments, zVAD -fmk was not able to reverse the effects on HL-60 cells of
either TFS or etoposide (data not shown). Since it has been recently reported that zVADfmk does not universally protect cells from apoptosis, (Zhang, Sheng and Loh, 1999;
Amarente-Mendes et al., 1998), these experiments were repeated using another known
apoptosis inducer that acts through a different mechanism, sphingomyelinase (Smase)
(Fig 13). Again neither the effects of TFS nor of Smase were reversed by zVAD-fink.
Therefore, cytological analyses were performed to determine whether TFS treatment
induces the appearance of morphological and cytoarchitectural features of apoptosis in
HL-60 cells.
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Effects of TF5 on HL-60 Cell Proliferation:
Cytological Analysis
Cells were treated with vehicle or excessive doses of known apoptosis inducers
(ceramide, sphingosine) or maximal doses of TFS and then examined for membrane
blebbing, nuclear and chromatin condensation, apoptotic nuclear bodies and cell
shrinkage by light microscopy (LM). The terminal deoxynucleotidyl transferase dUTP
nick-end labeling (TUNEL) assay was used to assess by fluorescence microscopy (FM)
the induction of apoptotic DNA damage in the cells. The cytological effects of lipid
messengers known to induce apoptosis (Jarvis et al., 1997) are presented in Table 2.
These compounds caused the appearance in HL-60 cells of cytological features (i.e.
membrane blebbing, DNA damage) characteristic of apoptosis. In contrast, the data
presented in Table 3 shows that treatment with maximal doses of TF5 did not induce
cytological features associated with apoptosis. These experiments confirm that apoptosis
is not involved. Rather, TFS appears to induce cytostasis in HL-60 cells.

HPLC Analysis of TFS: Reverse Phase
TFS can be separated on isoelectric focusing gels into several components. Three
peptide components. Ta,, TP4, and MB-3S have been purified and sequenced. None of
these purified thymosin peptides (Tat, T^4 , MB-3S) had any effect on HL-60 cells in
pharmacological doses (Fig 14). Therefore, TFS was further purified using reverse- phase
HPLC (rpHPLC). Of the sixty resulting fractions, only fraction 24 demonstrated
consistent inhibition of HL-60 cell proliferation (Fig IS). As an anti proliferative agent,
fraction 24 was ten times more potent than TFS (Fig 16).
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HPLC Analysis of TF5: Size Exclusion
Due to the limited amount of sample produced by rpHPLC we were unable to
obtain sufficient quantities for thorough analysis and purification of TFS-fraction 24.
Therefore, TFS was also separated by size exclusion gel permeation HPLC. Because TFS
contains a number of small peptides, a standard curve was generated using proteins in the
molecular weight range of lOSO Da to 66 kDa (Fig 17). None of the resulting TFS
fractions consistently demonstrated significant inhibition of HL-60 cell proliferation (Fig
18).
Gel Filtration Chromatography Analysis of TFS
To more effectively purify useful quantities of its anti proliferative activity, TFS
was separated on the basis of molecular size by gel filtration chromatography on a
Sephadex G-SO gel bed with a flow rate of 1.4 mL/min. The standard curve for protein
standards in the molecular weight range 1060 Da to 24 kDa is shown in Fig 19.
According to this standard curve, the most active TFS firaction (fraction S) corresponds to
approximately 20 kDa molecular weight. Since TFS contains only peptides of less than
IS kDa, it is possible that oligomerization of component peptides may occur in the
biologically active form of the extract. In Fig 20, the protein concentrations are compared
to the anti-proliferative activity of the fractions resulting from the separation of TFS (SO
mg) by gel filtration chromatography.
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Gel Electrophoresis of TF5 and Biologically
Active TF5 Fractions
Molecular weight estimates of the TFS fractions were performed under reducing
and denaturing conditions using polyacrylamide gel electrophoresis. Biologically active
TFS gel filtration chromatography fractions were separated on Tris- glycine SDS- PAGE
gels. Mobilities were compared to those of wide- range molecular weight protein
standards (2.S kDa - 200 kDa) shown in Fig 21. The behavior of TFS and two less
purified thymus extract preparations ( TP12900S86, TP2169066) are also shown. The
most predominant band of the active fraction on these gels corresponds to a molecular
weight estimate of less than 14 kDa (Fig 22). Bis- Tris gels were used to achieve better
separation of very low molecular weight species. Mobilities were compared to those of
wide- range molecular weight protein standards (2.S kDa - 200 kDa). The standard curve
for these gels is shown in Fig 23. Fig 24 shows that the TFS fractions are still
heterogeneous, and further purification is required before sequencing can be attempted.
Four predominant bands are present in the molecular weight range 5000-15000.

Effects of Other Thymic Extract Preparations
On HL-60 Cell Proliferation:
Comparison to TF5
To determine whether the anti- tumor activity present in TF5 can be isolated from
other thymus extracts, its effects were compared to those of less purified bovine thymus
extract preparations. Thymus preparations (TP, TAP) inhibited the proliferation of HL-60
cells in a manner similar to that of TF5 (Fig 25). Reverse-phase HPLC fractions of one
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thymus acetone preparation, TAP, contain both inhibitory and stimulatory factors (Fig
26). The Lowry protein profile of TAP fractions indicates that the area of greatest
inhibition of tumor cell proliferation corresponds to the protein peak, whereas the highly
stimulatoiy activity precedes the protein peak. TAP fraction 20 inhibited HL-60 cell
proliferation by as much as 80%, whereas fraction 10 induced substantial proliferation in
the cells. A dose response comparing the potency of TAP fraction 20 in HL-60 cell
inhibition to that of TF5 and the parent extract (TAP) is shown in Fig 27. As with TF5,
further separation of the anti-proliferative activity by size-exclusion HPLC was
unsuccessful (data not shown).
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CHAPTER 4

DISCUSSION
Thymosin fraction 5 is a partially purified protein extract of the bovine thymus
that contains at least 30-40 heat-stable polypeptides. It is frequently used as a
replacement for an intact thymus in various in vitro and in vivo models. TFS stimulates
multiple immune functions and exhibits anticancer effects, making it attractive as a
potential source of medications to treat immune disorders and cancers. We have
previously reported (Spangelo et al., 1998) that TFS inhibits the proliferation of the rat
pituitary adenoma MMQ and rat C6 glioma cell lines in vitro, but induces only a modest
suppression of proliferation in the CRL7686 human melanoma cell line. TFS has also
been shown to thwart the proliferation of certain murine leukemia cells (Khaw et al.,
1973; Schultz et al., 1976; Petro et al., 1982) and human acute lymphoblastic T cell
leukemia cells in vitro (Ho et al., 1983,1983a). Furthermore, TFS normalized the in vitro
immune responses of human T cells from leukemia patients (ALL, CLL, AML) (Schafer,
et al., 1976).
The in vitro effects of TFS on human acute myelogenous leukemia cell
proliferation have not been tested, however, and the presumed activity in TFS that is
responsible for the inhibition of tumor cell proliferation has not been identified. In
addition, the mechanism of TFS inhibition of myelogenous leukemia cells has not been

46
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determined. Therefore, we studied the effects of TFS on HL-60 human acute
myelogenous leukemia cells.
HL-60 Cell Culture
The HL-60 cell line responded well in continuous suspension culture under the
conditions described, maintaining high cell viability (>90%) throughout the culture
period. The cell-doubling time was 24-30 hours during the logarithmic growth phase.
HL-60 cells also formed colonies spontaneously in soft agar in a manner that was
dependent on initial cell plating density.

Effects of TFS on HL-60 Cell Proliferation:
Viable Dye Exclusion and MTT Assays
We found that TFS inhibited the proliferation of HL-60 cells in vitro in a dose,
time and cell number- dependent manner. As with the MMQ and C6 neuroendocrine
tumor cell lines (Spangelo et al., 1998), the suppression of HL-60 proliferation was
accompanied by only a modest reduction in cell viability. The TFS EDso for HL-60 cell
growth suppression was approximately 400 pg/mL, and maximal inhibition (< 20% of
control cultures) was achieved with a concentration of 800 pg/mL at 72 hours of
incubation. In contrast, 1000 pg/mL of TFS only moderately suppressed CRL7686
human melanoma cell proliferation (60% of control cultures at 1000 pg/mL), with an
EDso of approximately 700 pg/mL. As with the MMQ, C6 and CRL7686 cells, none of

the purified thymosin peptides (Ta,, Tp4 , MB-3S) had any effect on the proliferation of
the HL-60 cells. Together, these results indicate that TFS may not exert a non-specific
effect in the inhibition of HL-60 cell proliferation.
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TFS had less effect on HL-60 proliferation at higher initial cell densities.
Depending on the cell density, concentrations as low as 100 pg/mL significantly
suppressed HL-60 cell growth. However, concentrations below 600 pg/mL did not block
the proliferation at an initial plating density of 30x10* cells/well. The effects of low
concentrations of TFS were also increasingly less dramatic with time, suggesting that an
anti-TFS activity accumulates in the HL-60 cell cultures. Similar effects were observed in
the MMQ cell line, and we found that S0% MMQ-conditioned medium largely reversed
the TFS inhibition of MMQ cells (Spangelo et al., 1998), supporting the hypothesis that
MMQ cells release a factor that interferes with TFS inhibition of cell growth. However,
in characterizing the HL-60 cell line, Gallagher and colleagues (1979) found that HL-60conditioned medium does not stimulate the in vitro proliferation or clonogenic potential
of normal bone marrow cells or leukemic leukocytes. In a later study, this group analyzed
the ability of HL-60 conditioned medium and concentrated HL-60 cell extracts to
stimulate their own clonogenic potential. None of the HL-60 conditioned preparations
were able to stimulate the colony formation of HL-60 cells or normal bone marrow cells
(Ruscetti et al., 1981). This indicates that HL-60 cells may not release an autonomous
growth factor that interferes with the action of TFS.
Additionally, we found that HL-60 cell counts and MTT-derived optical density
(OD) units were significantly reduced within 24 hours in TFS treated cultures as
compared with control cells. TFS suppression of HL-60 cell proliferation was not
diminished by the removal of TFS after the initial incubation period. Further, when TFS
in medium was exposed to HL-60 cells for 24 hours, it was not able to inhibit the
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proliferation of naïve cell cultures. It appears that the HL-60 cells metabolize a
consumable factor found in TF5.

Effect of TF5 on HL-60 Cell Proliferation:
Clonogenic Assays
In semi-solid medium such as agar, HL-60 cells form spontaneous colonies
without the necessity for exogenous growth factors (Gallagher et al., 1979; Ruscetti et al.,
1981). TFS inhibited the cloning potential of HL-60 cells in a dose-dependent manner,
suggesting that an activity in TFS prevents the occurrence of HL-60 colony formation in
agar. As with the MTT and viable dye exclusion assays, the TFS EDso for the inhibition
of colony formation was approximately 400 pg/mL, and maximal inhibition was
achieved with a concentration of 800 pg/mL. Exposure to 400 pg/mL of TFS for as little
as 4 hours retarded colony formation and 800 pg/mL of TFS for 8 hours was sufficient to
completely inhibit HL-60 clonogenic potential. We suggest that a thymic peptide may
prevent metastatic growth of human leukemia cells in situ. The results of the clonogenic
assay are consistent with those obtained using the MTT and trypan blue exclusion assays,
both of which demonstrated a decrease in cell viability and proliferation in the presence
ofTFS.

Mechanism of TFS Inhibition of
HL-60 Cell Proliferation
We used known inducers (etoposide, sphingomeylinase) and inhibitors (zVADfink) of apoptosis to study the mechanism of this inhibition. The broad-spectrum caspase
inhibitor zVAD-fink failed to reverse the effects of TFS and the apoptosis inducers
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etoposide (VP-16) and sphingomyelinase. That is, the clonogenic potential of the cells
was not protected in any of the test groups. Since it has been recently reported that (1)
zVAD-fink fails to protect HL-60 cells from other apoptosis inducers (Zhang, Sheng and
Loh, 1999) and (2) zVAD-fink did not rescue the clonogenic potential of HL-60 cells
from apoptosis induced by etoposide, staurosporine and Actinomycin-D (AmarenteMendes et al., 1998), these experiments were repeated using another known apoptosis
inducer that acts through a distinct mechanism, sphingomyelinase (Smase). Again neither
the effects of TFS nor of Smase were reversed by zVAD-fmk. Therefore, cytological
analysis by light microscopy and the TUNEL assay were used to further investigate the
mechanism of TFS action on HL-60 cells. These experiments confirm that apoptosis is
not involved. Thus, TFS appears to induce cytostasis in HL-60 cells. This is in contrast
to our observations with the MMQ and C6 neuroendocrine cell lines, in which apoptosis
was the apparent mechanism of TFS inhibition. The data in our study may demonstrate a
new biological property of TFS: the inhibition of cell proliferation and the induction of
cytostasis in human myeloblastic leukemia cells in vitro.

Identification of TFS Anti-Proliferative
Activity
We believe that the anti-proliferative activity in TFS is due to one or more peptide
components. On the basis of dry weight, TFS is 99% protein with a small amount of
carbohydrate and essentially no nucleotide (Hooper et al., 197S). Several previously
purified components of TFS (i.e. Ta,, Tp4, MB-35) had no discernible effect on HL-60
cell proliferation. Therefore, TFS was further fractionated using rpHPLC. Further
purification of TFS into sixty one-minute fractions by rpHPLC resulted in one fraction
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(fraction 24) that significantly inhibited HL-60 cell proliferation. It is noteworthy that
none of the previously purified thymosin peptides elute in this fraction. Fraction 24 was
ten times more potent than TF5, indicating substantial purification of the anti
proliferative activity. The rpHPLC process did not provide enough material for further
purification, but it does support our argument that the observed inhibition of HL-60 cells
is due to an activity present in TF5 rather than a non-specific effect (i.e. not all fractions
affected the cells).
To generate useful quantities of the anti-proliferative activity in TFS, it was
fractionated by size exclusion gel permeation HPLC. None of the resulting fractions
consistently demonstrated significant inhibition of HL-60 cell proliferation. This may
indicate that a component necessary for biological activity was removed, or that the
fractionation process modified the active molecule.
To avert this possibility and to generate larger sample quantities, we separated
substantial quantities of biologically active TFS fractions on the basis of molecular size
by gel filtration column chromatography on a Sephadex gel bed. Although the fabrication
process for TFS extract excludes proteins larger than IS kDa, we separated biologically
active fractions of TFS corresponding to approximately 20 kDa that inhibited HL-60 cell
proliferation by more than 80%. This may suggest that oligomer formation occurs in a
biologically active form of thymosin components. We also obtained moderately active
(i.e. fraction 34, Fig 20) fractions of approximately 1200- ISOO MW. Data obtained by
Hooper and colleagues (1975) also suggested the presence of subunits in purified
fractions of TFS. They purified a moderately active molecule with a calculated molecular
weight of 12,200 from TFS. When this preparation was subjected to gel filtration under
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reducing and denaturing conditions, it eluted as two protein peaks of MW 3200 and 2400,
suggesting that the preparation is composed of polypeptide subunits.
Estimates of molecular weight were performed under reducing and denaturing
conditions on polyacrylamide gels. Separation on 4- 20% Tris-Glycine polyacrylamide
gels did not substantially resolve the fractions, which migrated as a dense group of bands
in the range of 6 kDa to 22 kDa. This suggests that the fractions may contain multiple
peptides of similar molecular weight. Pre-cast 12% Bis-Tris polyacrylamide gels were
used to achieve better separation of very low molecular weight components. On these
gels, TF5 and active fractions of TF5 show a strong band density at approximately 6 kDa,
and three other predominant bands in the 5000-15000 molecular weight range.
To determine whether the anti-tumor activity present in TF5 can be isolated from
other thymus extracts, we compared the anti-proliferative effects of TF5 on HL-60 cells
to the effects exerted by less purified bovine thymus preparations. Thymus acetone
preparations (acetone precipitation) inhibited HL-60 cell proliferation in a dosedependent manner. One such preparation, TAP, was subjected to reverse-phase HPLC.
The activity profile for these fractions has two regions of inhibition, and a large peak of
stimulation. The area of greatest anti-proliferative activity, TAP fraction 20, corresponds
to the protein peak, while the growth-stimulating activity (fraction 10) precedes it. We
hypothesized that separation of the two activities would allow more pronounced
concentration-dependent effects of the anti-proliferative action of TAP fiaction 20 (TAP20) on HL-60 cells. TAP-20 was 40 times more effective than TAP in the inhibition of
HL-60 cell proliferation. As with TF5, we were unable to purify this activity further by
size-exclusion HPLC. Given the substantially concentrated anti proliferative activity in
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this preparation, alternative methods of purification (i.e. gel filtration column
chromatography) seem warranted. Likewise, two-dimensional isoelectric focusing on
SDS-PAGE gels would provide better resolution of the biologically active TF5 fractions.

Conclusions
We conclude that TF5 inhibits the proliferation of HL-60 human myelogenous
leukemia cells in a dose and time-dependent manner in vitro. This inhibition does not
seem to be due to a nonspecific effect. Nor does it appear that a factor secreted by the
cells disrupts the effects of TF5. Our observations suggest the HL-60 cells metabolize a
consumable factor in TF5. Thymosin also inhibited the colony-forming potential of HL60 cells in soft agar. We suggest that a thymic peptide may prevent metastatic growth of
human leukemia cells in situ. TF5 apparently does not induce apoptosis in the HL-60
cells, but it may induce cytostasis. Thus, our observations may demonstrate a new
biological property of TF5: the inhibition of cell proliferation and colony-forming
potential, and the induction of cytostasis in HL-60 human myelogenous leukemia cells in
vitro.
Useful quantities of a low molecular weight, biologically active TF5 activity can
be separated by gel filtration chromatography. Further purification is necessary to
identify and sequence the active component(s). None of the previously purified thymosin
peptides elutes in the biologically active rpHPLC fiaction of TF5. However, TF5-like
activity was observed in several thymus acetone powders that are less purified than TF5.
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These studies suggest that a thymic hormone immune surveillance mechanism
may suppress the onset of certain types of leukemia. The isolation of the active thymosin
peptide may provide a novel treatment strategy for the management of certain leukemias.
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Effect of ITS on HLéOGefl Viability
Time(hr)
48

Chav

24

72

VeUde

%.6±0l5

% 9±a7

97^±a4

100 ^inL

93L8±09

% 9±a7

% 4±a6

400pg/mL

9L5±L8

9L2±aS

9I5±a9

OOOpg/mL

%4±3.0

614±&2

6i2± S 3

Table 1. Effect of TF5 on the viability of HL-60 human myelogenous leukemia celts.
2.4 xIO^ HL-60 cells were exposed to TF5 for 72 hr. Results are the averages of
percent viability from three independent experiments.
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Treatment

DNA Damage
(FM)

Cell Death
(LM)

% V eh icle C ontrol

Vehicle

1 +/-1%

2 +/-1%

Ceramide

5 +/- 2%

27 +/-1%

Sphingosine

11+/. 4%

89+/-1%

Table 2. Cytological Effects of Sphineolipid Messengers on HL-60 Cells. Cells were
exposed to vehicle or ceramide or sphingosine (10 pM) for 9 hr. DNA damage was
visualized by fluorescence microscopy (FM) after staining with FITC-dUTP in the
presence of TdT. Morphologic features of apoptotic cell death were observed by light
microscopy (LM) after staining with conventional Wright-Giemsa. Values are
expressed as the mean ± SEM of four determinations.
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Treatment

DNA Damage
(FM)

Cell Death
(LM)

% V d iic le C ontrol

CONTROL

3 +/-1%

2 +/-1%

TF5 24 Hrs.

3 +/-1%

2 +/- 1%

TF5 48 Hrs.

5 +/- 2%

1 +/- 1%

TF5 72 Hrs.

4+ /-l%

4 +/- 2%

Table 3. Cytological Effects of TF5 on HL-60 Cells. Cells were exposed to a maximal
dose of TF5 for 72 hr. Cells exhibiting DNA damage were visualized by fluorescence
microscopy (FM) after staining with FITC-dUTP in the presence of TdT.
Morphologic features of apoptotic cell death were observed by light microscopy
(LM) after staining with conventional Wright-Giemsa. Values are expressed as the
mean ± SEM of four determinations.
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Figure 1. Thvmus Dependent Senescence of Immunity in Man. Schematic showing
the relationship between decreased thymus function, thymic hormone levels, and
thymus-dependent immunity.
^Reprinted from Goldstein et al., 1975, by permission of the author.
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Figure 2. Schematic showing the locations of thvmosin peptides in the thvmus
Gland. TFS and TF6 have been found throughout the cortex and medullary
epithelial cells (Hirokawa, McClure, and Goldstein, 1982; Schuurman et al, 1985).
Adapted from Janeway and Travers, 1994
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Figure 3. Principle hypothesis of this study. Because TFS generally stimulates
thymus-dependent inununity, and because ant-tumor immunity is under thymic
control, we hypothesized that TFS would directly inhibit leukemia cell proliferation.
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Figure 4. Proliferation of HL«60 human myelogenous leukemia cells in continuous
suspension culture. HL-60 cells (15 x 10^ cells/well) were cultured in a humidified
atmosphere of S% €02-95% air at 37**C in phenol-free RPMI-1640 supplemented
with 10% heat-inactivated fetal bovine serum, sodium pyruvate, nonessential amino
acids and antibiotics. Cell numbers were determined by standard microscopy every
24 hr. The mean doubling time for the data shown is 28.5 hr. The data are expressed
as the mean ± SEM of groups consisting of four observations.
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Figure S. TPS inhibits HL-60 human myelogenous leukemia cell proliferation.
Cultured HL-60 cells (7S x 10^ cells/well) were exposed to either vehicle (complete
RPMI-1640) or different concentrations of TPS for 24-72 hr, and cell concentrations
were determined by standard microscopy and viable dye exclusion.
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Figure 6. TF5 inhibits HL-60 human myelogenous leukemia cell proliferation: effect
of incubation period. Cultured HL-60 ceils (20 x 10^ cells/well) were exposed to
either vehicle (complete RPMI-1640) or different concentrations of TF5 for 24-72 hr,
and cell proliferation was determined by the MTT viability assay.
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Figure 7. TF5 inhibits HL-60 human myelogenous leukemia cell proliferation: effect
of cell number. Cultured HL-60 cells (5-30 x 10^ cells/well) were exposed to either
vehicle (complete RPMI-1640) or different concentrations of TF5 for 72 hr, and cell
proliferation was determined by the MTT viability assay.
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Figure 8. TPS inhibits HL-60 human myelogenous leukemia cell proliferation: effect
of pretreatment period. Cultured HL-60 cells (80 x 10^ cells/mL^ were pretreated
with 800 pg/mL TPS for 24 hr and cultured in complete RPMI-1640, or cells were
exposed to either vehicle or 800 pg/mL TPS. Cell concentrations were determined by
standard microscopy and viable dye exclusion at 24 to 96 hr.
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Figure 9. TF5 inhibits HL-60 human myelogenous leukemia cell proliferation: effect
of HL-60 conditioning of TFS. Cultured HL-60 cells (80 x 10^ cells/well) were either
treated with vehicle (complete RPMI-1640), TFS (800 pg/mL), or TFS that was
removed from HL-60 cells following a 24 hr incubation period. In addition, HL-60
cells were exposed to TFS that was diluted in a 24 hr HL-60 cell- conditioned
medium. Cell concentrations were determined by standard microscopy and viable
dye exclusion.
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Figure 10. HL-60 human myelogenous leukemia cell colonv-forming potential in soft
agar is dependent on initial cell plating density. Cultured HL-60 cells were plated at
varying initial cell numbers and then cultured for 14 days in agar.
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Figure 11. TFS inhibits the cionogenic potential of HL-60 human myelogenous
leukemia cells: effect of TFS dose. Cultured HL-60 cells HOO x 10^ celWml.) were
pretreated with 100-800 pg/mL TFS for 24 hr and then cultured for 14 days in agar
(300 cells/well).
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Figure 12. TFS inhibits the cionogenic potential of HL-60 human myelogenous
leukemia cells: effect of pretreatment period. Cultured HL-60 cells (100 x 10^
cells/mL) were pretreated with 800 pg/mL TFS for 4,8 or 24 hr and then cultured for
14 days in agar.
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Figure 13. TFS inhibits the cionogenic potential of HL-60 human mveloeenous
leukemia cells: effect of pre-incubation of HL-60 cells with an apoptosis inhibitor.
Cultured HL-60 cells (100 x 10^ cells/mL) were pretreated with 800pg/mL TFS for
24 hr or pre-incubated in the presence of lOOpM zVAD-fink (in DMSO) and then
pretreated with 800pg/mL TFS for 24 hr or 200mU sphingomyelinase for 9 hr. The
cells were then cultured for 14 days in agar. Colony numbers were determined by
microscopy.
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Figure 14. Effect of purified thvmosin peptides on HL-60 human myelogenous
leukemia cell proliferation: comparison to TFS. Cultured HL-60 cells f20 x 10^
cells/well) were exposed to vehicle (RPMI-1640, supplemented) or TF5, Toi, Tp< or
MB-3S for 72 hr. Only TFS significantly suppressed cell proliferation. The data are
expressed as the mean ± SEM of groups consisting of four observations.
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Figure IS. Effect of HPLC fraction 24 on HL-60 human myelogenous leukemia
cell proliferation: comparison to TFS. Cultured HL-60 cells (20 x 10^ cells/well)
were exposed to vehicle (complete RPMI-1640), fraction 24 or TFS for 72 hr, and cell
proliferation was determined by the MTT viability assay. Inset shows the UV profile
at 280nm of the HPLC separation of TFS.
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Figure 16. Effect of HPLC fraction 24 on HL-60 human myelogenous leukemia cell
proliferation: comparison to TFS. Cultured HL-60 cells (20 x 10^ cells/well) were
exposed to vehicle (complete RPMI-1640), fraction 24 or TFS for 72 hr, and cell
proliferation was determined by the MTT viability assay.
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Figure 17. Protein standard curve for size exclusion HPLC. Retention times are
plotted against the log of the MW of each protein standard (BSA, trypsin, cytochrome
c, and bradykinin). The data are expressed as the mean ± SEM of groups consisting of
three separate sample injections.
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Figure 18. Effect of HPLC fractionated TF5 on HL-60 human myelogenous leukemia
cell proliferation. Cultured HL-60 cells (20 x 10^ cells/well) were exposed to either
vehicle (complete RPMI-1640) or different firactions of size exclusion HPLCseparated TFS for 72 hr, and cell proliferation was determined by the MTT viability
assay.
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Figure 19. Protein standard curve for gel filtration chromatography. Distribution
coefficient (K) values for the protein standards trypsin (MW 24 kOa), cytochrome c
(MW 12kDa), and bradykinin (MW 1060 Da) are on Sephadex G-SO are shown. The
flow rate was 1.40 mL/min.
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Figure 20. Effect of gel filtration chromatography- separated TFS fractions on HL-60
human myelogenous leukemia cell proliferation: comparison to Lowrv protein values.
TFS was loaded onto the column (50 mg) and 1-minute fractions were collected.
Protein concentrations were determined by the Lowry method. Cultured HL-60 cells
(20 X 10^ cells/well) were exposed to individual fractions for 72 hr and cell
proliferation was determined by the MTT reaction assay. The cell proliferation data
are expressed as the mean ± SEM of groups consisting of four observations.
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Figure 21. Separation of TF5 and thvmus preparations (TPl on 4-20% Tris-glvcine
gels. TFS (S-SO pg) and thymus preparations (S pg) were reduced with P*
mercaptoethanol and electrophoresis was carried out at 125V (constant) for
iq)proximately 60 minutes. Molecular weight standards (MW Stds) are 200 kDa to 2.5
kDa.
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Figure 22. Separation of TF5 and active TFS gel filtration chromatography fractions
on 4-20% SDS- PAGE gels. Samples were reduced with P-mercaptoethanol and
electrophoresis was carried out at 12SV (constant) for approximately 60 minutes.
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Figure 23. Protein standard curve for gel electrophoresis on 12% Bis-tris eels.
Electrophoresis was carried out at 200V (constant) for approximately 30 minutes.
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Figure 24. Separation of TFS and active TFS pel filtration chromatography fractions
on 12 %Bis-Tris polvacrvlamide gels. 3-Spg of sample was loaded onto each well,
and electrophoresis was carried out at 200V (constant) for approximately 30 minutes.
Fractions 2 and 3 are from the separation of lOmg of TFS. Fractions 4,5, and 6 are
from the separation of SO mg of TFS.
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Figure 25. Effects of TF5 and thvmus acetone preparations on HL-60 human
myelogenous leukemia cell proliferation. Cultured HL-60 cells (20 x 10^ cells/well)
were exposed to vehicle (RPMI-1640, supplemented) or TFS, TAP, TPl or TP-2 for
72 hr and then proliferation was measured by the MTT reaction assay. All thymus
preparations inhibited HL-60 cell proliferation. The data are expressed as the mean ±
SEM of groups consisting of four observations.
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Figure 26. Effect of HPLC-fractionated TAP on HL-60 human myelogenous
leukemia cell proliferation. Cultured HL-60 cells (20 x 10^ cells/well) were exposed
to either vehicle (complete RPMI-1640) or different fractions of HPLC separated
TAP for 72 hr, and cell proliferation was determined by the MTT viability assay.
Protein concentrations of individual fractions were determined with the Lowry assay.
Data for HL-60 cell proliferation are expressed as the mean ±SEM of groups
consisting of four observations.
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Figure 27. Effect of TAP fraction 20 on HL-60 cell proliferation: comparison to TAP
and TFS. Cultured HL-60 ceils (20 x 10^ cells/well) were exposed to vehicle (RPMI1640, supplemented) or TFS, TAP, or TAP fraction 20 for 72 hr and proliferation was
measured by the MTT reaction assay. The data are expressed as the mean ± SEM of
groups consisting of four observations.
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